The role of methotrexate (MTX), given with cyclosporine (CS), after HLA-identical sibling bone marrow transplantation needs to be defined. In all, 80 patients with hematologic malignancies were enrolled in a prospective randomized trial. All were given BuCy conditioning. The 40 patients in the CS arm received CS 3 mg/kg/day intravenously, with subsequent oral dosing. Patients in the CS þ MTX arm received, in addition to CS, MTX intravenously, 15 mg/m 2 on day 1, and 10 mg/m 2 on days 3, 6, and 11. Transplantation-related mortality was low in both groups of patients (13 vs 11% for CS vs CS þ MTX groups, P ¼ 0.94). The CS group had a significantly higher frequency of chronic graft-versus-host disease (56 vs 32%, P ¼ 0.05). After a median follow-up of 22.1 months (5.1-47.8 months), three of 30 vs 10 of 28 patients with acute leukemia/myelodysplastic syndrome (MDS) in CS group vs CS þ MTX group relapsed (P ¼ 0.01) yielding better overall survival for patients with acute leukemia/MDS treated with CS (P ¼ 0.02). After HLAidentical sibling bone marrow transplantation, immunosuppression with CS, with or without MTX, resulted in similarly low transplantation-related mortality. In acute leukemia/MDS, decreased relapse with patient survival prolongation was observed in the CS group. The main method of post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation has been the administration of immunosuppressive agents, including methotrexate (MTX), cyclosporine (CS), and glucocorticosteroids.
immunosuppression; cyclosporine; methotrexate
The main method of post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation has been the administration of immunosuppressive agents, including methotrexate (MTX), cyclosporine (CS), and glucocorticosteroids. [1] [2] [3] Early clinical trials were characterized by high transplantation-related mortality, of up to 42% of patients, especially those given CS or MTX alone.
1,2,4-11 Over half of the cases of transplantationrelated mortality were due to interstitial pneumonitis, with or without documented cytomegalovirus (CMV) disease. Post-transplant immunosuppression utilizing combinations of immunosuppressive agents showed a lower incidence of acute graft-versus-host disease (GVHD) and transplantation-related deaths. 3, [6] [7] [8] [9] [10] [11] Although combination therapy is widely accepted for post-transplant immunosuppression in various settings of allogeneic hematopoietic cell transplantation, including HLA-identical sibling bone marrow transplantation, 12 the optimum regimen for post-transplant immunosuppression in the latter requires further investigation, primarily because recent improvements in the management of patients with GVHD and resulting infectious complications, such as CMV, have been shown to significantly decrease the incidence of transplantationrelated mortality after allogeneic hematopoietic cell transplantation. 13 In addition, several studies have reported increased relapse rates of underlying leukemia resulting from combined immunosuppression after HLA-identical sibling bone marrow transplantation. 7, 14 These findings indicate that, in HLA-identical sibling bone marrow transplantation, where the genetic disparity between the donor and the patient is relatively small, optimum posttransplant immunosuppression should be strong enough to suppress graft-versus-host reaction, thus decreasing transplantation-related mortality, but not so strong as to suppress the graft-versus-leukemia effect, thus decreasing the relapse of leukemia.
In 1999, we initiated a randomized, prospective trial comparing CS alone with a combination of CS þ MTX as post-transplant immunosuppression regimens in patients with hematologic malignancies undergoing HLA-identical sibling bone marrow transplantation. We sought to evaluate whether an increase in transplantation-related mortality would result when MTX was omitted from the post-transplant immunosuppression regimen. The primary end point of the study was the frequency of transplantation-related mortality. The secondary end points were the frequencies of acute and chronic GVHD, the relapse of leukemia, and the overall survival of the patients.
Patients and methods

Patients and transplantation procedure
Patients 15-50 years of age with histologically confirmed hematologic malignancies, Karnofsky performance scale of X70, and with HLA-identical sibling donor(s) were eligible for the study. HLA-matching for donor selection was based on serologic typing for HLA-A, -B, and -C antigens (Terasaki Oriental HLA (72) Well Tray, Lot #23A, One Lambda Inc., Canoga Park, CA, USA) and molecular typing for HLA-DRB1 antigen (LiPA HLA-DRB1, Innogenetics, Gent, Belgium). Other eligibility criteria included adequate liver function (total bilirubin o2.0 mg/dl and aspartate aminotransferase (AST) o120 U/l), renal function (creatinine o2.0 mg/dl), and cardiac function (ejection fraction 445% on multi-gated blood pool scan). The protocol was approved by the institutional review board, and all patients and donors gave written informed consent.
The random assignment of post-transplant immunosuppression was performed in blocks of four at the start of the conditioning regimen, with stratification per disease status at bone marrow transplantation, and was based on the morphologic examination of bone marrow on the day before the initiation of conditioning. Standard risk was defined as acute leukemia in first complete remission (CR), chronic myelogenous leukemia (CML) in first chronic phase, and myelodysplastic syndrome (MDS) of refractory anemia (RA) or RA with ringed sideroblasts (RARS) categories. Otherwise, the patients were considered to have high-risk disease.
All patients were kept in laminar air-flow rooms. All had a triple lumen central venous catheter inserted. Ciprofloxacin and acyclovir were administered for gut decontamination and viral prophylaxis, respectively. Patients were given a BuCy regimen (busulfan 4 mg/kg/day orally, without blood level targeting, on days À7 to À4 and cyclophosphamide 60 mg/kg/day by intravenous infusion on days À3 to À2) for conditioning therapy. 15 Since August 2002, intravenous busulfan (Busulfex, Orphan Medical, Minnetonka, MN, USA), at a dose of 3.2 mg/kg/day, has replaced oral busulfan. Hyperhydration and mesna were given for the prevention of cyclophosphamide-induced hemorrhagic cystitis. All cellular blood products were leukocyte depleted and irradiated prior to transfusion. Immunoglobulin 500 mg/kg was administered intravenously on day -7, every other week until day 120, and monthly until day 180. Heparin was administered at a rate of 100 U/kg/day from day -7 to 30, but was discontinued if there was clinically significant bleeding or if the partial thromboplastin time exceeded 1.2 times the upper limit of control. Total parenteral nutrition was given where indicated. Each patient received a non-T-cell-depleted bone marrow graft, which had been harvested from the posterior iliac bones of the donor under general anesthesia.
Patients randomized to receive CS only for posttransplant immunosuppression received CS 1.5 mg/kg by intravenous infusion every 12 h starting on day À1 and were switched to an oral dose when oral intake became feasible. Patients randomized to receive a combination of CS þ MTX received, in addition to CS, intravenous MTX 15 mg/m 2 on day À1 and 10 mg/m 2 on days 3, 6, and 11. CS levels were monitored weekly, with a reference blood level of 100-300 ng/ml. The dose of CS was reduced 50% when serum creatinine levels rose to twice baseline and was discontinued when serum creatinine levels rose to thrice baseline. The dose of MTX was reduced 50% when serum creatinine rose to twice baseline, total bilirubin rose to 2-5 mg/dL, AST rose to 200-400 U/l, or grade II mucositis developed. MTX was withheld when serum creatinine rose to thrice baseline, serum bilirubin exceeded 5 mg/dl, AST exceeded 400 U/l, or grade III mucositis developed. In both groups of patients, CS dose was decreased by 10% every month starting 60 days after bone marrow transplantation when there was no evidence of GVHD.
All patients received a daily dose of 450 mg granulocyte colony-stimulating factor (G-CSF) intravenously, starting on day 5 of the infusion of donor bone marrow until the peripheral blood absolute neutrophil count (ANC) was over 3000/ml. The same dose of G-CSF was administered when ANC decreased below 1000/ml and was continued until ANC recovered to 3000/ml. CMV pp65 antigenemia was assayed weekly until day 100. When positive, preemptive treatment with ganciclovir was initiated.
All patients were monitored prospectively for the occurrence of adverse events, including GVHD, regimenrelated toxicities, and infections. A diagnosis of acute 16 and chronic 17 GVHD and hepatic veno-occlusive disease (VOD) 18 was made according to the published criteria. Oral mucositis and diarrhea were graded by Common Toxicity Criteria, version 2.0 (National Cancer Institute, USA). A polymerase chain reaction (PCR)-based procedure utilizing short tandem repeats of DNA was used to analyze hematopoietic chimerism 1, 2, and 3 months after bone marrow transplantation. 19 
Statistical analysis
Assuming a transplantation-related mortality of 10% for patients given CS þ MTX for post-transplant immunosuppression, an increase of 30% in the CS arm would require 31 patients in each arm by one-sided test (significance level of 0.05 and power of 0.80). Categorical variables were compared using the w 2 test. Continuous variables were compared using Student's t-test or the Mann-Whitney U-test. Time-event variables (neutrophil and platelet engraftment, occurrence of acute and chronic GVHD, transplantation-related mortality, leukemia relapse, and survival) were plotted by the Kaplan-Meier method and compared using the log-rank test. Transplantation-related mortality was defined as any death without relapse of leukemia or MDS. For the calculation of time to leukemia relapse, those patients who died without recurrent leukemia or MDS were censored at the time of the death.
Results
Patient characteristics
Between July 1999 and May 2003, 80 patients were enrolled, 40 each in the CS and CS þ MTX arms, and all were evaluable for the study. There were no significant differences between the two groups of patients with respect to various clinical and transplant characteristics (Tables 1 and 2 ). The mean age of the patients was 32 years (range, 15-49 years) in the CS arm and 35 years (range, 15-48 years) in the CS þ MTX arm. For patients with acute leukemia who were transplanted in their first CR status, the median duration from the diagnosis of acute leukemia to bone marrow transplantation was 135 days (range, 94-240 days) in the CS arm and 140 days (range, 80-275 days) in the CS þ MTX arm UPN 106, Table 2 , P ¼ 0.78 by Mann-Whitney U-test). All patients received bone marrow cells from HLA 8-antigen-identical siblings. A total of 18 patients in the CS arm and 23 in the CS þ MTX arm underwent sex-mismatched bone marrow transplantation. In the CS þ MTX arm, two patients received two doses each of MTX, 25 patients received three doses each, and 13 patients received four doses each. Most dose reductions were due to grade II-III oral mucositis.
Engraftment
All patients in the study achieved ANC 41000/ml. The median numbers of days to ANC 41000/ml were significantly less for patients in the CS arm by 5 days (Table 3 ). The median number of days to platelet 420 000/ ml was also less for the CS group (P ¼ 0.05). Hematopoietic chimerism was analyzed from DNA extracted from the peripheral blood of the patients, and all 37 patients tested in each arm showed donor-dominant hematopoiesis of X90% by 3 months after bone marrow transplantation.
Transplantation-related mortality
The median follow-up period of the surviving patients was 22.1 months (range, 5.1-47.8 months). Eight patients, four in each arm, died without evidence of relapsed leukemia or MDS, between 44 and 568 days after bone marrow transplantation (P ¼ 0.94, Table 2 , Figure 1a ). The 2-year projected rates of transplantation-related mortality were 13% for the CS arm and 11% for the CS þ MTX arms. Causes of death are listed in Table 2 . None of the patients in the CS arm died due to acute or chronic GVHD. One patient in the CS þ MTX group died on day 61 due to stage 4 acute gut GVHD and sepsis, and one patient in the same group committed suicide after suffering from depression related to the sequelae of central nervous system bleeding and was considered as an event. When we considered patients with standard risk disease only, the 2-year projected rates of transplantation-related mortality were 10% (2/30) for the CS arm and 7% (2/31) for the CS þ MTX arm (P ¼ 0.96).
Acute and chronic GVHD and regimen-related toxicities
In all, 17 patients (43%) in the CS arm and 10 (25%) in the CS þ MTX arm developed acute GVHD 9-55 days after bone marrow transplantation (P ¼ 0.06, Table 3 ). Eight patients (20%) in each treatment arm developed grade II-III acute GVHD (P ¼ 0.89), but none of the patients in either group developed grade IV acute GVHD. The median days after bone marrow transplantation to the onset of acute GVHD was shorter for the patients in the CS arm (day 15 (range, days 9-52) vs day 37.5 (range, days 13-55), P ¼ 0.04 by Mann-Whitney U-test), and patients in the CS arm had relatively greater involvement of the skin. Table 1 Baseline characteristics of patients given CS or CS+MTX for post-transplant immunosuppression One patient in the CS arm and three in the CS þ MTX arm died or relapsed with leukemia before day 100 after bone marrow transplantation and were not evaluable for chronic GVHD. In total, 22 patients (56%) in the CS arm and 12 (32%) in the CS þ MTX arm developed chronic GVHD 69-325 days after transplantation (P ¼ 0.05, Table 3 ). Extensive stage chronic GVHD occurred in 16 patients (41%) in the CS arm and seven (19%) in the CS þ MTX arm (P ¼ 0.04). There were no significant between-group differences in the number of days until onset (day 154 (range, days 100-236) vs day 151 (range, days 69-325) for CS vs CS þ MTX groups, P ¼ 0.72) or in the platelet count at onset (132 000/ml (range, 43 000-232 000/ml) vs 105 000/ml (range, 42 000-265 000/ml), P ¼ 0.13).
While the majority of patients in the CS arm developed grade I-II oral mucositis, the majority of patients in the CS þ MTX arm developed grade III-IV mucositis (P ¼ 0.001, Table 3 ). The frequencies of VOD and diarrhea were similar in the two groups of patients. The proportions of patients who developed positive results on CMV pp65 assays and received pre-emptive treatment with ganciclovir Table 3 Engraftment, acute and chronic GVHD, and regimen-related toxicities in patients given CS or CS+MTX for post-transplant immunosuppression were not significantly different (Table 3) . One patient developed CMV hepatitis and treated with ganciclovir with complete recovery (UPN 142).
Relapse of leukemia and MDS
Of 58 patients with acute leukemia/MDS, 13 (three in the CS arm and 10 in the CS þ MTX arm) relapsed 73-635 days after bone marrow transplantation, yielding a 2-year projected cumulative incidence of relapse rates of 12% for the CS arm and 46% for the CS þ MTX arm (P ¼ 0.01, Table 2 , Figure 2a) . Patients with CML were evaluated by bone marrow examination with cytogenetic study at the time of bone marrow recovery after bone marrow transplantation. In patients with Ph-positive metaphases, bone marrow examinations were repeated monthly. Reverse transcriptase-PCR for Bcr-Abl transcripts were performed from peripheral blood mononuclear cells monthly for 3 months then 3 monthly for 2 years after transplantation. Of 22 patients with CML, one in the CS þ MTX arm, who was transplanted in the accelerated phase, showed increasing percentages of Ph-positive metaphases until day 63, then converted to complete cytogenetic and molecular remission status on day 94 after discontinuation of CS (UPN 106, Table 2 ). None of the other 21 patients with CML experienced cytogenetic or hematologic relapse.
Overall survival
A total of 16 patients, five in the CS arm and 11 in the CS þ MTX arm, died (P ¼ 0.10, Table 2, Figure 1b ). When we considered the patients with acute leukemia/MDS only, four of 30 patients in the CS arm and 11 of 28 in the CS þ MTX arm died (P ¼ 0.02, Table 3, Figure 2b ).
Discussion
Our randomized prospective study showed that, in patients younger than 50 years of age receiving an HLA-identical sibling bone marrow transplantation, post-transplant immunosuppression with CS, with or without a short course of MTX, resulted in similarly low transplantation-related mortality, with 2-year projected rates of 13% for CS alone and 11% for CS þ MTX arms. Several randomized trials have investigated immunosuppression regimens after HLAidentical sibling bone marrow transplantation. Earlier trials 4, [6] [7] [8] [9] [10] [11] showed that patients who received post-transplant immunosuppression with a combination of CS þ MTX had lower frequencies of grade II-IV acute GVHD and transplantation-related deaths than patients who received CS alone or MTX alone. Transplantationrelated mortality in patients given single agent posttransplantation immunosuppression ranged from 38-42%, whereas, of 50 patients with hematologic malignancies given CS alone, 18 (36%) died due to transplantationrelated causes, including 7 from CMV interstitial pneumonitis, 5 each from idiopathic interstitial pneumonitis and infections and 1 from VOD. 6 In contrast to clinical trials performed in the 1980's, lower transplantation-related mortality rates have been obtained in recent clinical trials, [20] [21] [22] where the patients were given GVHD prophylaxis with CS only. In a randomized trial comparing lowdose CS with low-dose CS þ low-dose MTX in patients with AML, the transplantation-related mortality rate was 11% for patients in the CS arm, compared with 17% for patients in the CS þ MTX arm (P ¼ 0.6), and none of these patients died of CMV or idiopathic interstitial pneumonitis. 20 In patients with severe aplastic anemia given GVHD prophylaxis with CS alone, the transplantation-related mortality was 19%, and none of these patients died of interstitial pneumonitis. 22 In both of the above trials, as well as in ours, the CMV antigenemia status of the patients was monitored regularly, and pre-emptive treatment with antiviral agents, such as ganciclovir, was initiated when patients were CMV positive. Detection of CMV infection by antigenemia assay or PCR-based methods and preventive or pre-emptive use of antiviral agents have been associated with a significant reduction in CMV diseases, especially CMV interstitial pneumonitis. 13 With CMV diseases having become less significant as a cause of transplantation-related deaths, the role of MTX as an agent for lowering transplantation-related mortality after HLA-identical sibling bone marrow transplantation may be less significant. Other changes in the general care given to the patients undergoing bone marrow transplantation may have also contributed to the overall reduction of transplantation-related deaths. These include pre-and posttransplant uses of leukocyte-filtered blood products, which may reduce the risk of viral infections and of pre-transplant allosensitization of the patients, 23 and the administration of growth factors such as G-CSF after bone marrow infusion. 24 Another important finding of our study is the significant reduction of relapse of patients with acute leukemia/MDS following administration of post-transplant immunosuppression with CS alone (3/30), compared with those given CS þ MTX (10/28, P ¼ 0.01). Our observation is consistent with previous studies, suggesting that GVHD prophylaxis with less intense immunosuppression was associated with a lower relapse rate of acute leukemia. 6, 7, 25, 21 The early survival benefit in patients given GVHD prophylaxis with CS þ MTX, as demonstrated by a lower rate of transplantation-related mortality, was offset by a nonsignificant increase in the relapse rate of acute myelogenous leukemia (29 vs 20%, P ¼ 0.23). 7 In a randomized trial comparing low-dose (1 mg/kg/day) and high-dose (5 mg/kg/day) CS for GVHD prophylaxis in patients with acute leukemia, the actuarial risks of relapse were 20% for the low-dose and 52% for the high-dose CS groups (P ¼ 0.001), whereas the 2-year leukemia-free survival rate was better for the lowdose (58%) than for the high-dose (32%) arm (P ¼ 0.02). 25 The importance of the intensity of post-transplant immunosuppression with regard to relapse of acute leukemia needs to be emphasized in view of the wider application of allogeneic hematopoietic cell transplantation utilizing nonmyeloablative conditioning regimens, where eradication of residual leukemic clones is more dependent on the graftversus-leukemia effect than the cytotoxic effect of the conditioning regimen. Further prospective randomized trials in patients with acute leukemia, with appropriate stratification according to disease status and leukemia subtypes, and preferably with the primary end points being leukemia relapse and overall survival of patients, are necessary to confirm our findings. In the meantime, posttransplant immunosuppression with CS alone, without MTX, may be considered after HLA-identical sibling bone marrow transplantation, especially in patients with highrisk disease -acute leukemia/MDS.
Although most studies comparing CS with CS þ MTX as GVHD prophylaxis showed an increased frequency of grade II-IV acute GVHD in patients who received CS alone, 6, 8, 11, 20 our study showed similar frequencies in the two treatment arms (20% for each, P ¼ 0.89). However, the rate of grade I acute GVHD was higher in the CS arm (nine cases) than in the CS þ MTX arm (two cases), and many of these cases were characterized by skin rashes and febrile episodes that occurred early after bone marrow transplantation during the periengraftment period, but which responded well to treatment with systemic glucocorticosteroids. 26 Similar frequencies of grade II-IV acute GVHD have been observed in patients with severe aplastic anemia treated with CS alone (38%) or CS þ MTX (30%, P ¼ 0.37), and the onset of acute GVHD was shorter for the CS alone group. 22 Low frequency of grade II-IV acute GVHD in our study is in contrast to other studies from the United States and Europe, which reported the frequency of up to 54%. 4, [6] [7] [8] [9] [10] [11] Low frequency of acute GVHD has been reported in Japanese population. 27 Although the discrepancies between the studies cannot be readily explained, they may be due in part to the heterogeneity of the patient populations.
The rate of chronic GVHD in patients given CS alone for post-transplant immunosuppression (56%) was significantly higher than that observed in patients given CS þ MTX (32%, P ¼ 0.05), a difference likely due to a lack of lymphotoxic effect of MTX in the early period after transplantation or an excess of grade I acute GVHD contributing to chronic GVHD. 28 Chronic GVHD is a phenomenon associated with antileukemia effect, [29] [30] [31] and the correlation between a higher frequency of chronic GVHD and decreased relapse of acute leukemia in the CS arm in our study should be investigated in future clinical trials. Further careful follow-up of our patients, especially in CS alone arm, is necessary for possible long-term complications of chronic GVHD. In agreement with previous findings, 4, 6, 11 our study also showed a significant shortening of the median neutrophil engraftment time, and a reduced severity of oral mucositis, with CS alone relative to CS þ MTX.
It should be noted that all patients in our study were conditioned with BuCy regimen, which showed significant differential biologic effects from conditioning with cyclophosphamide plus total body irradiation in terms of longterm complications. In AML, nonsignificant differences in disease-free and overall survivals were reported. 32 In conclusion, our study showed that, in HLA-identical sibling bone marrow transplantation in a Korean patient population, post-transplant immunosuppression with CS alone in patients younger than 50 years old was associated with a low transplantation-related mortality, a slightly increased acute GVHD (mainly grade I), and increased chronic GVHD when compared with patients treated with CS þ MTX. These findings suggest that, in HLA-identical sibling bone marrow transplantation, MTX may be omitted from the regimen of post-transplant immunosuppression without a significant increase in transplantationrelated deaths in certain patient populations with low risk for acute GVHD. In patients with acute leukemia, CS without MTX may decrease the rate of relapse and improve patient survival.
